Global health diplomacy and India

Global health diplomacy must confront power asymmetry

Global health diplomacy can only succeed if power is shared across the Global South and North, not just health priorities. Read more »
neutrality of merit

The myth of neutral merit in education and hiring

India's definition of #merit rewards privilege while ignoring structural barriers that marginalised candidates must overcome. #reservation #upsc #jobquotas Read more »
Rio BRICS Summit

BRICS economic goals clash with India’s Quad strategy

New Delhi’s embrace of #Quad risks diluting #BRICS plans for a non-dollar trade system, leaving the bloc short of consensus and capital. #dedollarisation Read more »
critical minerals, India-Chile CEPA

India-Chile CEPA to boost New Delhi’s critical minerals quest

Tariff liberalisation poses familiar risks for India-Chile CEPA's thrust on clean energy goals. #CEPA #criticalminerals Read more »
public health

Lessons for India from Trump’s public health revamp

Trump administration’s sweeping cuts in public health spending offers valuable lessons India cannot afford to copy. #Publichealth #Trump Read more »
Indian industry's China dependence

Foxconn recall exposes Indian industry’s China problem

The Foxconn episode and the curbs on minerals reveal the fragility of Indian industry's manufacturing supply chains. Read more »
Multilateral lenders, MDBs

Multilateral lenders must evolve to fund climate action

Multilateral lenders face obsolescence unless they pivot to finance climate action and support the Global South. #MDBs #climateaction Read more »
ELI scheme

ELI scheme: India’s ₹99,000 crore job push may not suffice

The government’s ELI scheme will boost job generation, but deeper reforms needed to tackle youth unemployment. #ELI #unemployment Read more »
Lessons for India’s RDI scheme

RDI Scheme: Five China-inspired fixes for India’s innovation gap

India’s #RDI scheme could raise #R&D to 1.2 % of #GDP—if policymakers copy #China’s tight sector focus and let markets steer projects. #evs #ai Read more »
pharma industry

Pharma industry needs to pivot beyond generics

India's pharma industry must pivot to biosimilars and specialty drugs as global generics margins shrink and trade risks rise. #pharma #generics Read more »